Venus Remedies

What does Venus Remedies do?

Venus Remedies Ltd is a pharmaceutical and biotechnology company focused on global injectable launches, with a market cap of Rs 575 Cr and reported net sales of 195 Cr and net profit of 21 Cr for March 2025. The company has a P/E ratio of 16.00 and a return on equity of 6.69%.

Overview: <BR>Venus Remedies Ltd is a pharmaceutical and biotechnology company that specializes in the global launch of injectables, operating within the micro-cap market.<BR><BR>History: <BR>Incorporated in 1989, Venus Remedies Ltd was initially known as Venus Glucose Pvt Ltd and became a Public Limited Company in 1994. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 195 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 21 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 575 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.29 <BR>Return on Equity: 6.69% <BR>Price to Book: 1.05<BR><BR>Contact Details: <BR>Address: S C No 857 Cabin No 10 2nd Flr, N A C Manimajra Chandigarh Chandigarh (U T): 160101 <BR>Email: investorgrievance@venusremedies.co <BR>Website: http://www.venusremedies.com

Has Venus Remedies declared dividend?

Yes, Venus Remedies Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 23, 2013. However, the dividend yield is 0%, indicating that returns are primarily from price appreciation rather than dividend income.

Venus Remedies Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 23 Sep 13<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 28.73%, with a dividend return of 0%, resulting in a total return of 28.73%.<BR><BR>Over the past year, the price return was 38.64%, with a dividend return of 0%, leading to a total return of 38.64%.<BR><BR>In the 2-year period, the price return was 89.69%, and the dividend return was 0%, culminating in a total return of 89.69%.<BR><BR>For the 3-year period, the price return was 94.53%, with a dividend return of 0%, resulting in a total return of 94.53%.<BR><BR>In the last 4 years, the price return was 31.32%, and the dividend return was 0%, giving a total return of 31.32%.<BR><BR>Over the past 5 years, the price return was an impressive 775.0%, with a dividend return of 0%, leading to a total return of 775.0%.<BR><BR>Overall, while Venus Remedies Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the returns are primarily driven by price appreciation rather than dividend income. The significant total returns over various periods highlight strong price performance.

Who are the peers of the Venus Remedies?

Venus Remedies' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Shukra Pharma, Medicamen Biotec, Kerala Ayurveda, Jenburkt Pharma, and Accent Microcell. In terms of management risk, growth, and capital structure, Venus Remedies ranks average compared to its peers, with a 1-year return of 45.78%.

Peers: The peers of Venus Remedies are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Shukra Pharma., Medicamen Biotec, Kerala Ayurveda, Jenburkt Pharma, and Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and Shukra Pharma. Average management risk is present at Venus Remedies, Medicamen Biotec, Jenburkt Pharma, and Accent Microcell, while below Average management risk is noted at Kerala Ayurveda. In terms of growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is found at Shukra Pharma. Average growth is present at Venus Remedies, and Below Average growth is noted at Divi's Lab., Torrent Pharma, Medicamen Biotec, and Jenburkt Pharma. Excellent capital structure is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Medicamen Biotec, while Good capital structure is found at Torrent Pharma and Shukra Pharma, and Average capital structure is noted at Venus Remedies, while Below Average capital structure is present at Kerala Ayurveda.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Medicamen Biotec has the lowest at -16.64%. Venus Remedies' 1-year return of 45.78% is lower than Divi's Lab. but higher than the lowest peer. Additionally, the peers with negative six-month returns include Medicamen Biotec and Torrent Pharma.

Who are in the management team of Venus Remedies?

As of March 2023, the management team of Venus Remedies includes Pawan Chaudhary (Chairman & Managing Director), Manu Chaudhary (Joint Managing Director), Peeyush Jain (Deputy Managing Director), and several independent directors, overseeing the company's operations and governance.

As of March 2023, the management team of Venus Remedies includes:<BR><BR>1. Pawan Chaudhary - Chairman & Managing Director<BR>2. Manu Chaudhary - Joint Managing Director<BR>3. Peeyush Jain - Deputy Managing Director<BR>4. Ashutosh Jain - Executive Director<BR>5. Gilbert Wenzel - Independent Director<BR>6. S. K. Chadha - Independent Director<BR>7. Neha Kodan - Company Secretary & Compliance Officer<BR>8. Navdeep Sud - Independent Director<BR>9. Savita Gupta - Independent Director<BR>10. Akshansh Chaudhary - Whole-time Director<BR>11. Nps Monga - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, overseeing various aspects of the company's operations and governance.

Who are the top shareholders of the Venus Remedies?

The top shareholders of Venus Remedies include Sunev Pharma Solutions Limited with 17.21%, individual investors with 46.81%, and notable public shareholder Pradeep Kumar Jain at 2.78%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Venus Remedies include Sunev Pharma Solutions Limited, which holds the highest promoter stake at 17.21%. Additionally, individual investors collectively hold 46.81% of the shares. Among public shareholders, Pradeep Kumar Jain is notable with a holding of 2.78%. The company also has participation from five foreign institutional investors (FIIs), who collectively own 1.34% of the shares. There are no pledged promoter holdings, and no mutual funds are currently involved with the company.

How big is Venus Remedies?

As of 24th July, Venus Remedies Ltd has a market capitalization of 693.00 Cr, with recent net sales of 647.89 Cr and a net profit of 45.33 Cr. Shareholder's funds are 487.55 Cr, and total assets amount to 626.82 Cr.

As of 24th July, Venus Remedies Ltd has a market capitalization of 693.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Venus Remedies reported Net Sales of 647.89 Cr and a Net Profit of 45.33 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 487.55 Cr and Total Assets of 626.82 Cr.

Is Venus Remedies technically bullish or bearish?

As of November 11, 2025, the trend is bullish with moderate strength, supported by daily moving averages and monthly indicators, though caution is advised due to mixed signals in shorter timeframes and a bearish RSI on the monthly chart.

As of 11 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with moderate strength. Key indicators driving this stance include the daily moving averages which are bullish, and the monthly Bollinger Bands and KST also indicating bullish momentum. However, the weekly MACD and KST are mildly bearish, suggesting some caution in the short term. The RSI on the monthly timeframe is bearish, indicating potential overbought conditions. Overall, while there are mixed signals in the shorter timeframes, the prevailing trend is bullish.

How has been the historical performance of Venus Remedies?

Venus Remedies has shown consistent growth in net sales and profits, with net sales increasing from 321.89 crore in March 2019 to 647.89 crore in March 2025, and profit after tax recovering to 45.32 crore in March 2025 from previous losses. The company's earnings per share improved significantly, reflecting overall resilience and positive financial performance.

Answer:<BR>The historical performance of Venus Remedies shows a trend of increasing net sales and profits over the years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>Venus Remedies has demonstrated a consistent growth in net sales, rising from 321.89 crore in March 2019 to 647.89 crore in March 2025. The total operating income followed a similar trajectory, reaching 647.89 crore in March 2025, up from 555.51 crore in March 2023. The company's operating profit (PBDIT) also increased, peaking at 84.50 crore in March 2025, while profit before tax surged to 71.83 crore in the same period, compared to a loss of 29.73 crore in March 2019. Profit after tax reached 45.32 crore in March 2025, reflecting a recovery from previous years of losses, including a significant loss of 10.00 crore in March 2020. The company's earnings per share (EPS) improved to 33.9 in March 2025, up from a negative EPS of -23.16 in March 2019. On the balance sheet, total assets increased to 715.72 crore in March 2025, while total liabilities rose to 715.72 crore, indicating a balanced growth. Cash flow from operating activities showed a positive trend, with a net cash inflow of 27.00 crore in March 2024, following a negative cash flow in previous years. Overall, Venus Remedies has shown resilience and growth in its financial performance over the years.

How has been the historical performance of Venus Remedies?

Venus Remedies has shown strong historical performance, with net sales increasing from 321.89 crore in March 2019 to 652.89 crore in March 2025, and a significant turnaround in profitability, achieving a profit after tax of 45.32 crore in March 2025 compared to a loss of 10.00 crore in March 2020. The company also improved its financial stability, with total assets growing to 715.72 crore and positive cash flow from operating activities.

Answer:<BR>The historical performance of Venus Remedies shows a positive trend in net sales and profitability over the years, with significant improvements noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Venus Remedies has demonstrated a steady increase in net sales, rising from 321.89 crore in March 2019 to 652.89 crore in March 2025. This growth is accompanied by a consistent rise in total operating income, which reached 652.89 crore in March 2025, up from 341.46 crore in March 2020. The total expenditure, excluding depreciation, also increased, amounting to 584.35 crore in March 2025. Despite this, the operating profit (PBDIT) has improved, reaching 84.49 crore in March 2025, compared to 46.09 crore in March 2020. Profit before tax has shown a remarkable recovery, climbing to 71.82 crore in March 2025 from a loss of 8.03 crore in March 2020. Consequently, profit after tax also increased to 45.32 crore in March 2025, reflecting a significant turnaround from a loss of 10.00 crore in March 2020. The company's total assets grew to 715.72 crore in March 2025, while total liabilities decreased to 1.69 crore, indicating improved financial stability. Cash flow from operating activities has been positive, with a net cash inflow of 27.00 crore in March 2024, further supporting the company's favorable financial trajectory.

Is Venus Remedies overvalued or undervalued?

As of November 12, 2025, Venus Remedies is considered undervalued with an attractive valuation grade, highlighted by a low PE ratio of 11.46 and strong stock performance, significantly outperforming the Sensex.

As of 12 November 2025, the valuation grade for Venus Remedies has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, particularly when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE ratio of 11.46, an EV to EBITDA of 5.29, and a PEG ratio of 0.06, all of which suggest that the stock is trading at a significant discount relative to its earnings growth potential.<BR><BR>In comparison to its peers, Venus Remedies stands out with a much lower PE ratio than Sun Pharma (35.94) and Divi's Lab (69.64), both of which are classified as expensive. Additionally, its EV to EBITDA ratio is considerably more attractive than those of its peers, reinforcing the undervaluation narrative. The company's recent stock performance has significantly outpaced the Sensex, with a year-to-date return of 70.13% compared to the Sensex's 8.10%, further supporting the conclusion that Venus Remedies is undervalued in the current market environment.

When is the next results date for Venus Remedies Ltd?

The next results date for Venus Remedies Ltd is 29 January 2026.

The next results date for Venus Remedies Ltd is scheduled for 29 January 2026.

Are Venus Remedies Ltd latest results good or bad?

Venus Remedies Ltd's latest results show strong growth in net profit and revenue, with net profit up 109.69% quarter-on-quarter and 473.50% year-on-year. However, concerns about operational inconsistencies and below-industry return on equity suggest caution regarding the sustainability of this performance.

Venus Remedies Ltd's latest results present a mixed picture. On one hand, the company has shown impressive growth in net profit and revenue for Q2 FY26. The net profit surged to ₹20.13 crores, reflecting a remarkable 109.69% increase quarter-on-quarter and an extraordinary 473.50% year-on-year growth. Revenue also rose significantly, reaching ₹192.75 crores, which is a 40.51% increase from the previous quarter and a 13.32% increase year-on-year.<BR><BR>Operating margins improved to 16.06%, up from 11.21% in the previous quarter, indicating better operational efficiency. However, these margins are still below the 18.34% achieved in Q4 FY25, highlighting some inconsistency in performance.<BR><BR>Despite these positive indicators, there are concerns regarding the sustainability of this growth. The company's profitability has exhibited pronounced quarterly volatility, raising questions about the quality of earnings. Additionally, while the stock has appreciated significantly over the past year, outperforming its sector peers, the underlying capital efficiency metrics, such as return on equity (ROE) at 10.52%, remain below industry standards.<BR><BR>In summary, while Venus Remedies has delivered strong growth in its latest results, the operational inconsistencies and volatility in margins suggest that caution is warranted regarding the sustainability of this performance.

Should I buy, sell or hold Venus Remedies Ltd?

Which are the latest news on Venus Remedies?

Why is Venus Remedies Ltd falling/rising?

As of 06-May, Venus Remedies Ltd's stock price is at 924.50, reflecting a decline of 2.43% and underperforming its sector. The stock has faced consecutive losses, significant selling pressure, and reduced trading volume, indicating a short-term bearish trend specific to the company.

As of 06-May, Venus Remedies Ltd's stock price is falling, currently at 924.50, which reflects a decrease of 23.05 or 2.43%. This decline is part of a broader trend, as the stock has underperformed its sector by 3.95% today and has experienced consecutive losses over the past two days, totaling a drop of 4.67%. <BR><BR>The stock also reached an intraday low of Rs 903, indicating significant selling pressure. Additionally, the trading volume has decreased sharply, with delivery volume on 05 May falling by 59.12% compared to the 5-day average, suggesting reduced investor participation. Although the stock remains above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, which may indicate a short-term bearish trend.<BR><BR>In contrast, the broader Pharmaceuticals & Drugs sector has gained by 2.41%, highlighting that the decline in Venus Remedies Ltd is specific to the company rather than the industry as a whole. Overall, these factors contribute to the stock's current downward movement.